Skip to Content

Join the 'Multiple Myeloma' group to help and get support from people like you.

Multiple Myeloma News

Related terms: Cancer, Malignant Plasmacytoma, Cancer, Multiple Myeloma, Cancer, Plasma Cell Dyscrasia, Cancer, Plasma Cell Myeloma, Malignant Plasmacytoma, Myeloma, Multiple, Plasma Cell Dyscrasia, Plasma Cell Myeloma, Plasmacytoma of Bone

Janssen Announces Darzalex (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

Posted 10 May 2018 by Drugs.com

HORSHAM, PA, May 7, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with Velcade (bortezomib)*, a proteasome inhibitor (PI); melphalan, an alkylating agent; and prednisone – VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ine ...

Many Ground Zero Rescue Workers Battling Cancer Years Later

Posted 26 Apr 2018 by Drugs.com

THURSDAY, April 26, 2018 – Many of the rescue workers who flooded the ruins of the World Trade Center after 9/11 now face their own private battles for survival, a pair of new studies shows. New York City Fire Department employees who worked at Ground Zero are expected to develop cancer at a greater rate than their fellow New Yorkers over the next decade, the first study found. For example, ...

FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma

Posted 10 Jan 2018 by Drugs.com

THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with ...

FDA Medwatch Alert: Keytruda (pembrolizumab) in Patients with Multiple Myeloma: FDA Statement - Two Clinical Trials on Hold

Posted 1 Sep 2017 by Drugs.com

ISSUE: Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment ...

Genmab Announces U.S. FDA Approval of Darzalex (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Posted 22 Jun 2017 by Drugs.com

Copenhagen, Denmark; June 16, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today the U.S. Food and Drug Administration (FDA) has approved the use of Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Darzalex is being ...

CAR T-cell Therapy May Thwart Multiple Myeloma

Posted 5 Jun 2017 by Drugs.com

MONDAY, June 5, 2017 – Genetically tuning a person's own immune cells to target cancer appears to provide long-lasting protection against a blood cancer called multiple myeloma, an early trial from China shows. The treatment, called CAR T-cell therapy, caused 33 out of 35 patients with recurring multiple myeloma to either enter full remission or experience a significant reduction in their ...

FDA Expands Indication for Revlimid (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

Posted 28 Feb 2017 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE) February 22,2017 – Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). The expanded indication ...

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing

Posted 4 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 4, 2017 – Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds. That could reduce side effects from the drug, known as zoledronic acid (Zometa), and increase cost savings, the researchers said. The drug is used to treat the spread of breast cancer, prostate cancer and multiple myeloma to ...

Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy

Posted 23 Nov 2016 by Drugs.com

HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.1 Clinical studies have shown that Darzalex, in combination with l ...

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who ...

Superior Results for Myeloma Drug That's Added Earlier in Treatment

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – A recently approved immunotherapy drug for a blood cancer called multiple myeloma can provide even better benefits if patients receive it earlier in their treatment, new clinical trial results show. Darzalex (daratumumab) reduced patients' risk of cancer progression by 70 percent when added to a standard two-drug regimen for people with recurring myeloma, said lead ...

Exercise May Cut Risk of 13 Cancers, Study Suggests

Posted 16 May 2016 by Drugs.com

MONDAY, May 16, 2016 – Exercise may significantly reduce your risk for many types of cancer, including some of the most lethal forms of the disease, a large review suggests. Working out for even a couple of hours a week appears to shrink the risk of breast, colon and lung cancer, said researchers who looked at 1.4 million adults. "Those are three of the four major cancers that affect Americans ...

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

Posted 16 May 2016 by Drugs.com

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries. There is no indication at this time that counterfeit BiCNU has entered the legitimate U.S. drug supply chain and no indication that any U.S. patients have received counterfeit BiCNU. See the FDA Alert ...

Radon in the Home May Be Linked to Blood Cancers in Women

Posted 3 May 2016 by Drugs.com

TUESDAY, May 3, 2016 – New research suggests a strong link between exposure to high levels of radon in the home and women's risk of blood cancers. Radon is a naturally occurring radioactive gas, the U.S. Environmental Protection Agency says. It's known to cause lung cancer and is the second leading cause of lung cancer in the United States, the researchers said. The American Cancer Society ...

FDA Grants Spectrum Pharmaceuticals Approval of Evomela (melphalan) for Injection

Posted 16 Mar 2016 by Drugs.com

HENDERSON, Nev., March 15, 2016 --(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Evomela for use in two indications: 1) use as a high-dose conditioning ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Osteolytic Bone Lesions of Multiple Myeloma, Myeloproliferative Disorders

Related Drug Support Groups

dexamethasone, Revlimid, Decadron, Cytoxan, cyclophosphamide, Velcade, doxorubicin, vincristine, Adriamycin, view more... carfilzomib, Kyprolis, Pomalyst, thalidomide, Alkeran, Neosar, lenalidomide, Thalomid, Adrenocot LA, Oncovin, Dexone, Adrenocot, bortezomib, pomalidomide, Darzalex, Ninlaro, melphalan, Medidex LA, Adriamycin RDF, Zonacort, Adriamycin PFS, Mozobil, Dexamethasone Intensol, Evomela, Dalalone, Baycadron, Farydak, Dalalone DP, Dalalone LA, Decaject, Empliciti, Decaject LA, Zema Pak, Dexpak Taperpak, Solurex, Medidex, Cytoxan Lyophilized, doxorubicin liposomal, plerixafor, panobinostat, daratumumab, ixazomib, elotuzumab, BiCNU, Gliadel, Vincasar PFS, Doxil, Hexadrol, Dexacorten, Decadron-LA, Solurex LA, Dexacen-4, carmustine, De-Sone LA, Dexacort-LA, Dexasone, Dexasone LA, Dexone LA, Primethasone, LoCort